Typical drugs include spironolactone 25 to 50 mg orally once a day and eplerenone 25 to 100 mg orally once a day (does not cause gynecomastia in males). Aldosterone antagonists can reduce mortality, including from sudden death, in patients with left ventricular ejection fraction (LVEF...
Multiple trials have shown that β-blockers reduce morbidity and mortality in patients with heart failure (HF), and these drugs, therefore, are commonly prescribed to patients with this condition. However, atrial fibrillation (AF) occurs in approximately one-third of patients with HF and, as ...
New class of drugs may reduce severe heart failure, prolong life in diabetics Therefore, in this study, we compared the cyclic fatigue resistances of K3 NiTi rotary instruments before and after surface treatment with HF. In addition, to visually examine any change induced in the instrument surfac...
Aims Beta-blockers reduce morbidity and mortality in chronic heart failure (HF) patients with reduced ejection fraction. However, there is heterogeneity in the response to these drugs, perhaps due to genetic variations in the beta 1-adrenergic receptor (ADR beta 1). We examined whether the Arg...
Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two tri
use of the joint frailty model may substantially reduce sample size requirements. In addition, using an end point that is acceptable to the Food and Drug Administration and the European Medicines Agency, such as recurrent ...
11-13 However, post hoc analyses from the Enhancing Recovery in Coronary Heart Disease trial12 indicated that prolonged SSRI treatment might reduce mortality and morbidity.14 Until now the Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) study is the only ...
Despite this consistent finding with multiple drug treatments in heart failure, there is ample evidence that older patients with heart failure are often under-treated with therapies that reduce mortality and morbidity.25 – 30 As with any study, this one has some limitations. Thi...
3. Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to...
It presents 3 critical articles that offer insight into current guidelines. First, an article describes HF treatment’s history, starting in 1986 when the 2 drugs considered the cornerstone of treatment—digoxin and diuretics—conferred no mortality benefits. A string of trials—begi...